<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943719</url>
  </required_header>
  <id_info>
    <org_study_id>SEPSIS2016</org_study_id>
    <secondary_id>2016/19SEP/401</secondary_id>
    <nct_id>NCT03943719</nct_id>
  </id_info>
  <brief_title>Clinical Impact of the FilmArray Blood Culture Identification Panel Performed on Positive Blood Cultures From Intensive Care Patients With Septicemia</brief_title>
  <acronym>SEPSIS2016</acronym>
  <official_title>The Impact of a Rapid Molecular Identification Test on Positive Blood Cultures From Critically Ill With Bacteremia: a Pre-post Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Molecular testing is a largely validated approach allowing rapid identification of positive
      blood cultures. However, due to its high cost and its limited information on susceptibility,
      it is considered as an add-on technique reserved for specific patient populations. In our
      study, we specifically evaluated molecular testing in a critical care setting and measured
      its impact on the therapeutic management of critically ill with positive blood cultures.
      Through the analysis of 110 positive blood culture episodes included in both pre- and post
      intervention period, we measured a drastic 14h-reduction of the time to administration of the
      optimal antimicrobial treatment with the use of the molecular approach.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Turn Around Time to optimal treatment of septicemia</measure>
    <time_frame>From positivity detection of positive blood culture to administration of optimal treatment (up to 48 hours)</time_frame>
    <description>Time in minutes</description>
  </primary_outcome>
  <enrollment type="Actual">139</enrollment>
  <condition>Septicemia</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FilmArray blood culture identification panel</intervention_name>
    <description>FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult intensive care unit patients with positive blood cultures
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult intensive care unit patients with positive blood cultures

        Exclusion Criteria:

          -  palliative care patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alexia VERROKEN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires St-Luc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques universitaires St-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FilmArray</keyword>
  <keyword>bacteremia</keyword>
  <keyword>septicemia</keyword>
  <keyword>clinical impact</keyword>
  <keyword>molecular testing</keyword>
  <keyword>identification</keyword>
  <keyword>positive blood culture</keyword>
  <keyword>optimal antimicrobial treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

